Compare Barrick Gold Corp (B) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs Heron Therapeutics Inc — how do they compare? Barrick Gold Corp trades at $40.48 (market cap $68.49B), while Heron Therapeutics Inc trades at $0.33 (market cap $63.41M). The key difference: Barrick Gold Corp is far larger — about 1080.1× Heron Therapeutics Inc's market cap, and Barrick Gold Corp pays a 1.71% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| B | HRTX | |
|---|---|---|
Market Cap | $68.49B | $63.41M |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $1.49 |
52-Week Low | $22.83 | $0.33 |
Enterprise Value | $66.08B | $161.31M |
Dividend Yield | 1.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $43.69, up 5.49% in 24 hours, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a $1.95 billion settlement with Newmont, and a robust cash flow trend highlight operational strength. The stock is near its consensus price target of $50.17, supported by a 66.67% analyst buy rating.
The outlook is positive due to earnings growth, favorable valuations, and strategic initiatives like the North American IPO. Risks include gold price volatility and execution of expansion plans. Upside potential exists if the company maintains its earnings momentum and capitalizes on gold market trends.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
